TNFSF10 and cancer: In addition to triggering a death receptor-mediated pro-apoptotic signaling pathway, TRAIL treatment can also activate intracellular pro-survival NF-κβ35, PI3K/Akt36, 37 and ERK38 signaling pathways, which indicates that TRAIL treatment alone may be insufficient for cancer therapy.